NCT05072782View on ClinicalTrials.gov

Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)

PHASE4UnknownINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 15, 2024

Conditions
Crohn Disease
Interventions
DRUG

Infliximab CT-P13

"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"

DRUG

Immunosuppressors (Thiopurines or Methotrexate)

"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"

Trial Locations (1)

75009

RECRUITING

GETAID, Paris

Sponsors

Collaborators (1)

Celltrion
All Listed Sponsors
collaborator

Celltrion

INDUSTRY

lead

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER